Education
About Us
Working with TipRanks
Follow Us
Resmed (RMD)
NYSE:RMD
RMD Analyst Ratings
Moderate Buy
9 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RMD Stock 12 Month Forecast
Average Price Target
$302.56
▲(20.30% Upside)
| Highest Price Target$335.00 | Average Price Target$302.56 | Lowest Price Target$270.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
$305
Buy
21.27%
Upside
Reiterated
12/09/25
Robert W. Baird
$320→$300
Buy
19.28%
Upside
Reiterated
11/03/25
UBS
$325→$335
Buy
33.20%
Upside
Reiterated
11/03/25
Piper Sandler
$270
Hold
7.36%
Upside
Reiterated
10/31/25
Oppenheimer
―
Hold
―
Reiterated
10/31/25
Mizuho Securities
$310→$300
Buy
19.28%
Upside
Reiterated
10/31/25
William Blair
―
Buy
―
Reiterated
10/31/25
RBC Capital
$300→$303
Buy
20.48%
Upside
Reiterated
10/31/25
Wells Fargo
$280
Hold
11.33%
Upside
Initiated
10/13/25
Citi
$330
Buy
31.21%
Upside
Reiterated
09/30/25
Resmed's Strategic Positioning and Growth Prospects: A Buy Recommendation by Laura SutcliffeWe are in line for FY26 but above thereafter, with VA consensus flatlining below 63%. We think this ignores remaining mix shift to the AirSense 11 and management ambitions for annual gross margin improvement through 2030.
Bank of America Securities
$300
Buy
19.28%
Upside
Reiterated
09/24/25
Resmed's Strategic Growth and Competitive Edge Support Buy Rating with $300 Price TargetWe hosted RMD London conference. Topics covered included WLD drugs impact, demand generation/capture, and margin expansion. We maintain our Buy rating given positive growth outlook. In particular, we appreciate RMD efforts to create and capture demand.
Stifel Nicolaus
―
Hold
―
Reiterated
08/13/25
We remain Hold‐rated on Resmed (RMD, $283.29, Hold) within our Sleep segment commentary.
J.P. Morgan
$310
Buy
23.26%
Upside
Reiterated
08/01/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
$305
Buy
21.27%
Upside
Reiterated
12/09/25
Robert W. Baird
$320→$300
Buy
19.28%
Upside
Reiterated
11/03/25
UBS
$325→$335
Buy
33.20%
Upside
Reiterated
11/03/25
Piper Sandler
$270
Hold
7.36%
Upside
Reiterated
10/31/25
Oppenheimer
―
Hold
―
Reiterated
10/31/25
Mizuho Securities
$310→$300
Buy
19.28%
Upside
Reiterated
10/31/25
William Blair
―
Buy
―
Reiterated
10/31/25
RBC Capital
$300→$303
Buy
20.48%
Upside
Reiterated
10/31/25
Wells Fargo
$280
Hold
11.33%
Upside
Initiated
10/13/25
Citi
$330
Buy
31.21%
Upside
Reiterated
09/30/25
Resmed's Strategic Positioning and Growth Prospects: A Buy Recommendation by Laura SutcliffeWe are in line for FY26 but above thereafter, with VA consensus flatlining below 63%. We think this ignores remaining mix shift to the AirSense 11 and management ambitions for annual gross margin improvement through 2030.
Bank of America Securities
$300
Buy
19.28%
Upside
Reiterated
09/24/25
Resmed's Strategic Growth and Competitive Edge Support Buy Rating with $300 Price TargetWe hosted RMD London conference. Topics covered included WLD drugs impact, demand generation/capture, and margin expansion. We maintain our Buy rating given positive growth outlook. In particular, we appreciate RMD efforts to create and capture demand.
Stifel Nicolaus
―
Hold
―
Reiterated
08/13/25
We remain Hold‐rated on Resmed (RMD, $283.29, Hold) within our Sleep segment commentary.
J.P. Morgan
$310
Buy
23.26%
Upside
Reiterated
08/01/25
Best Analysts Covering Resmed
1 Month
xxx
Success Rate
14/22 ratings generated profit
Average Return
+4.22%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +4.22% per trade.
3 Months
xxx
Success Rate
8/11 ratings generated profit
Average Return
+3.18%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +3.18% per trade.
1 Year
Success Rate
8/11 ratings generated profit
Average Return
+5.37%
reiterated a buy rating last month
Copying Craig Wong-Pan's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +5.37% per trade.
2 Years
xxx
Success Rate
19/25 ratings generated profit
Average Return
+20.09%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 76.00% of your transactions generating a profit, with an average return of +20.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RMD Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
0
0
0
0
0
Buy
18
26
29
19
15
Hold
4
4
8
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
30
37
23
19
Each month's total comprises the sum of three months' worth of ratings.
RMD Financial Forecast
RMD Stock Forecast FAQ
What is RMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Resmed’s 12-month average price target is 302.56.
What is RMD’s upside potential, based on the analysts’ average price target?
Resmed has 20.30% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RMD a Buy, Sell or Hold?
Resmed has a consensus rating of Moderate Buy which is based on 9 buy ratings, 4 hold ratings and 0 sell ratings.
What is Resmed’s price target?
The average price target for Resmed is 302.56. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $335.00 ,the lowest forecast is $270.00. The average price target represents 20.30% Increase from the current price of $251.5.
The highest analyst price target is $335.00 ,the lowest forecast is $270.00. The average price target represents 20.30% Increase from the current price of $251.5.
What do analysts say about Resmed?
Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of RMD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.